@article {Turner146, author = {Jane Turner and Chad He and Lisa Chung and Kelsey Baker and Jesse Hubbard and Elizabeth Rankin and Maggie Guerriero and Michael Boeckh and Karen Syrjala and Paul Martin and Ted Gooley and Stephanie Lee and Mary Flowers and Guang-Shing Cheng}, title = {Feasibility of home spirometry in patients with chronic graft-versus-host disease: a prospective observational study}, volume = {56}, number = {suppl 64}, elocation-id = {146}, year = {2020}, doi = {10.1183/13993003.congress-2020.146}, publisher = {European Respiratory Society}, abstract = {Background: Diagnosis of bronchiolitis obliterans syndrome (BOS) and other lung manifestations of chronic graft-versus-host disease (cGVHD) after hematopoietic cell transplantation (HCT) is often delayed. Home spirometry using Web-based technology may allow early diagnosis and intervention.Objectives: To determine the feasibility of home spirometry telemonitoring of at-risk patients post HCT.Methods: Allogeneic HCT patients \>18 years old with cGVHD performed weekly spirometry for 1 year using a wireless handheld device (GoSpiro, Monitored Therapeutics Inc). Reminders were sent via mobile application. Sustained FEV1 decline on three consecutive measurements prompted notification to the patient{\textquoteright}s physician. Conventional laboratory pulmonary function tests (PFTs) were performed every 3 months.Results: Of 39 patients, median compliance (defined as weeks performed/weeks in study) was 72\% (IQR 47{\textendash}87\%). The correlation between handheld and PFT FEV1 was r = 0.975 (p\<0.001), mean bias 0.098 L (lower limit -0.344 L, upper limit 0.541 L). Of 12 patients (31\%) diagnosed with BOS during the study period, 9 (23\%) had home data available demonstrating an antecedent FEV1 decline (Figure).Conclusions: Home spirometry in a high-risk HCT cohort is feasible for close monitoring of pulmonary function. Further studies are needed to determine its role in early diagnosis of BOS after HCT.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 146.This abstract was presented at the 2020 ERS International Congress, in session {\textquotedblleft}Respiratory viruses in the "pre COVID-19" era{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/56/suppl_64/146}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }